This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
ImmunoCellular Therapeutics, Ltd.(IMUC), a biotechnology company, presented promising clinical data from a Phase I trial evaluating ICT-107, the company's dendritic cell-based cancer vaccine product candidate for the treatment of glioblastoma. These data were reported at the American Society of Clinical Oncology Meeting in Orlando, Florida (Abstract #2032), and supplement the preliminary data from the completed clinical trial that the Company reported in December 2008.
We care about your feedback. Let us know how we can improve your CancerCompass experience.